secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2026-05-13T20:22:33+00:00
Accession:  0001125345-26-000040
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports Q1 loss, divests manufacturing, extends cash runway through 2028
--------------------------------------------------------------------------------

- Manufacturing operations sold to Bora Pharmaceuticals for $122.5M upfront; expected to close Q3 2026.
- Expanded ZYNYZ royalty monetization with Sagard: $60M received, up to $20M additional milestone.
- Q1 2026 net loss $36.8M ($0.58/share) vs $41.0M loss a year ago; revenue $20.8M (up from $13.2M).
- Cash and securities $154.2M at March 31, 2026; with proceeds, cash runway extended through 2028.
- Pipeline: Initial MGC026 ADC data expected mid-2026; MGC028 data H2 2026; MGC030 IND planned Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/0001125345-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000040/mgnx-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001125345-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer